MOUNTAIN VIEW, California, August 13 /PRNewswire-FirstCall/ -- BN ImmunoTherapeutics, Inc. has entered into a scientific partnership with the National Cancer Institute (NCI) in the United States. Under the Cooperative Research and Development Agreement (CRADA) the NCI and BN ImmunoTherapeutics will jointly develop new immunotherapies for the treatment of prostate cancer. Under the CRADA, BN ImmunoTherapeutics has rights to exclusively license intellectual property that results from this collaboration.
The company plans to in the future explore opportunities for extending this collaboration to further develop its cancer projects. By combining the company's expertise within cancer vaccine development with one of the world's leading centres of excellence within cancer research, the company is confident that this collaboration will result in new and innovative solutions to a disease area with high unmet medical needs as well as expand and accelerate the company's cancer activities.
Through the collaboration and a license agreement with the United States Public Health Service, the company has obtained rights to intellectual property rights covering a prostate cancer vaccine product candidate in late phase II clinical development. Data from key clinical studies with this vaccine candidate are currently being evaluated. Later in 2008 the company will inform the market about how this development project will have a future in the pipeline of the company.
About the NCI
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH) and is the United States federal government's leading cancer research organization.
- The National Cancer Institute (NCI) has played an active role in the development of drugs for cancer treatment for over 50 years. This is reflected in the fact that approximately one half of the chemotherapeutic drugs currently used by oncologists for cancer treatment were discovered and/or developed at NCI.
- NCI has supported the research efforts of at least 20 Nobel Prize winners. For approximately half of these Nobel laureates, NCI supported the awarded research.
- According to a 1996 NCI analysis of drugs approved by the FDA, two-thirds of the anti-cancer drugs approved as of the end of 1995 were NCI-sponsored Investigational New Drugs.
Dr. Jeffrey Schlom is the principal investigator at the NCI for this CRADA and is Chief of the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, NCI, NIH. Dr. Schlom is one of the leading figures in the area of cancer vaccine development, and has been improving and refining novel immunotherapeutic approaches for cancer in clinical studies for more than 10 years. The collaborative effort between BN ImmunoTherapeutics and NCI will hopefully provide urgently needed new therapies for patients suffering from prostate cancer.
Reiner Laus, MD, President & CEO of BN ImmunoTherapeutics said: "The NCI relationship opens up for us new and exciting opportunities within the field of cancer and we are proud to join forces with one of the most prestigious and well-established cancer research organisations in the world. In the collaboration with NCI, BN ImmunoTherapeutics benefits from the enormous expertise in cancer therapeutics development that is present in the NCI organisation."
Located in Mountain View, California, BN ImmunoTherapeutics is a subsidiary of Bavarian Nordic, headquartered in Denmark. BN ImmunoTherapeutics is developing immune based therapies for breast and prostate cancer.
Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology, MVA-BN(R), has been demonstrated in clinical trials to be one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company's third-generation smallpox vaccine, IMVAMUNE(R).
Bavarian Nordic is listed on the OMX Nordic Exchange Copenhagen under the symbol BAVA.
For more information, please visit: http://www.bavarian-nordic.com
"Safe Harbour" Statement under the Private Securities Litigation Reform Act of 1995:
Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. No "forward-looking statement" can be guaranteed, and actual results may differ materially from those projected. Bavarian Nordic undertakes no obligation to publicly update any "forward-looking statement", whether as a result of new information, future events, or otherwise. Additional information regarding risks and uncertainties is set forth in the current Annual Report and in Bavarian Nordic's periodic reports, if any, which we incorporate by reference.
|SOURCE Bavarian Nordic A/S|
Copyright©2008 PR Newswire.
All rights reserved